Seegene's product news
Seegene has received CE-IVD mark under European Union on In Vitro Diagnostics Medical Devices for Allplex™ MTB/MDR/XDRe Detection, Allplex™ MTB/MDRe Detection, Allplex™ MTB/XDRe Detection.
Based on Seegene's proprietary DPO™ and TOCE™ technology, these assays are multiplex real-time PCR assay that detects and identifies Mycobacterium tuberculosis (MTB) and 25 mutations associated with Multi-Drug Resistance (MDR) and 13 mutations associated with Extensively Drug Resistance (XDR). These assays enable to deliver MTB and Drug-resistant TB result in one day, which helps effective management of tuberculosis.
|Previous||Obtained CE-IVD marking for Allplex™ MG & AziR Assay||2019.01.22|
|Next||Obtained CE-IVD marking for Allplex™ Vaginitis Screening Assay||2019.03.25|